Subject matters | Details | Categories |
---|---|---|
Economic Development, Employment and Training, Health, Regional Development, Research and Development, Science and Technology
|
Seeking support from the Strategic Innovation Fund to support application of automation and AI technology in our recently opened cell and gene therapy manufacutring facility. The support will result in lower cost of life saving cell and gene therapy products.
|
Grant, Contribution or Other Financial Benefit, Policies or Program
|
Subject matters | Details | Categories | Added date |
---|---|---|---|
Economic Development, Employment and Training, Federal-Provincial Relations, Health, Regional Development, Science and Technology, Taxation and Finance
|
Strategic Investment Fund
Industrial Research Assistance Program
National Research Council funding for advanced therapy manufacturing
|
Legislative Proposal, Bill or Resolution, Policies or Program, Grant, Contribution or Other Financial Benefit
|
2024-11-15
|
End date of the last completed financial year: 2024-03-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
Innovation, Science and Economic Development Canada (ISED) | $913,068.00 | Yes |
Address:
661 University Ave.
Suite 1002 , ON Canada
Toronto, ON M5G 1M1
Canada
Telephone number:
416-978-3751
Fax number:
416-978-1368
Michael May, President and CEO
Centre for the Commercialization of Regenerative Medicine / Centre de commercialisation de la médecine régénérative is not a subsidiary of any other parent companies.
Centre for the Commercialization of Regenerative Medicine / Centre de commercialisation de la médecine régénérative is not a coalition.
The activities of Centre for the Commercialization of Regenerative Medicine / Centre de commercialisation de la médecine régénérative are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
WILLIAM MANTEL | No public offices held